MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 https://www.businesswire.com/news/h...-with-Three-Phase-3-Readouts-Expected-in-2026
GO TO THIS URL: https://ir.definiumtx.com/news-even...-44th-annual-j-p-morgan-healthcare-conference Click the Webcast Link at 5:15pm EST
Definium defines mental health applications for LSD in new awareness campaign https://www.fiercepharma.com/market...zempic-push-starring-justin-long-john-hodgman
PATENT GRANTED - $DFTX Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications https://ppubs.uspto.gov/api/patents...4LTRlZWQtYTBiOC0yYjdjZjJhZWMwNDAiLCJleHAiOjB9
Reminder All Older Posts prior to company name change can be found here: https://stockaholics.net/threads/mnmd-mindmed-inc.12024/
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital $DFTX www.investing.com/news/analyst-ratings/definium-therapeutics-stock-price-target-raised-to-36-from-20-at-rbc-capital-93CH-4462617
NJ Psilocybin Legislation Exposes Conflicts Between Advocates for Different Therapeutic Models https://www.lucid.news/nj-psilocybin-legislation-exposes-conflicts-between-advocates-for-different-therapeutic-models/ There’s a lot of tension in the article around “pharma gatekeeping” vs grassroots access to natural mushrooms. But if you strip away the politics and look at what actually came out of this, it reinforces something we’ve seen over and over. When states get serious, they default to hospital-based, physician-led, FDA-aligned models. Bullish for the synthetic companies
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted TherapyA Systematic Review and Meta-Analysis Gianluca Andri Florineth, MSc1,2; Isabell Klima, MD1; Anna Laura Boeker, MSc3 JAMA Netw Open Published Online: January 21, 2026 2026;9;(1):e2554843. doi:10.1001/jamanetworkopen.2025.54843 Key Points Question Is the quantity of psychological therapy associated with symptom reduction in psychedelic-assisted therapy (PAT) for depressive symptoms? Findings In this systematic review and meta-analysis of 12 controlled clinical trials with 733 participants, a greater amount of preparatory psychological therapy was associated with a larger reduction of depressive symptoms following psychedelic administration. Total duration of psychological therapy as well as quantity of postpsychedelic integration sessions were not significantly associated with symptom reduction. Meaning These findings suggest that preparation sessions before psychedelic administration may play an important role in optimizing treatment outcomes in PAT. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844126
